2024-04-04 12:43:31 ET
Summary
- Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder.
- End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024.
- The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033.
- MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030.
The last time I wrote about Mind Medicine (MindMed) Inc. ( MNMD ) was when it was gearing up to report results from a phase 2b study known as MMED008, which was using its drug MM120 for the treatment of patients with generalized anxiety disorder [GAD]. This was in a prior Seeking Alpha article entitled " Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts. " I believe it is important to provide an update on this biotech, because it has been able to achieve several positive developments since I last wrote about it....
Read the full article on Seeking Alpha
For further details see:
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data